surmount trial tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 With respect to the SURMOUNT-MAINTAIN

2018, doi: 10.1016/j.molmet.2018.09.009 Frayling et al., A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure, Cell Rep., vol

As mentioned, tirzepatide has a long half-life and is designed for once-weekly administration

GLP-1s have been approved for treatment of type 2 diabetes mellitus (T2DM) since 2005 and have also demonstrated high efficacy for weight loss (Jastreboff et al., 2022

Certificate information is lot-specific

When tirzepatide binds to GLP-1 receptors outside the brain, it triggers effects that have nothing to do with hunger